1型糖尿病发病年龄与年轻成人超额死亡及心血管疾病风险:全国登记队列研究
该研究基于瑞典国家糖尿病登记库及匹配对照的全国登记队列,纳入1998年1月1日至2012年12月31日期间至少一次登记的1型糖尿病患者,按发病年龄分为0-10、11-15、16-20、21-25、26-30岁五组,随访中位10年。共纳入27 195例1型糖尿病患者和135 178例匹配对照。调整糖尿病病程后,0-10岁发病组全因死亡HR 4.11(95%CI 3.24-5.22)、心血管病HR 11.44(7.95-16.44)、冠心病HR 30.50(19.98-46.57)、急性心梗HR 30.95(17.59-54.45);26-30岁发病组相应HR分别为2.83(2.38-3.37)、3.85(3.05-4.87)、6.08(4.71-7.84)、5.77(4.08-8.16),超额风险随发病年龄增大而降低,组间差异可达5倍。10岁前发病者女性寿命损失17.7年(95%CI 14.5-20.4),男性14.2年(12.1-18.2)。作者认为早发1型糖尿病可能需要加强心血管保护。
要点
- 0-10岁发病的1型糖尿病患者心血管病风险是对照的11.44倍(95%CI 7.95-16.44),急性心梗风险达30.95倍(17.59-54.45)。
- 发病年龄26-30岁组心血管病HR为3.85(95%CI 3.05-4.87),超额风险随发病年龄增大而降低,组间差异可达5倍。
- 0-10岁发病组全因死亡HR 4.11(95%CI 3.24-5.22),心血管死亡HR 7.38(3.65-14.94)。
- 10岁前发病者女性寿命损失17.7年(95%CI 14.5-20.4),男性14.2年(12.1-18.2),女性超额风险最高。
- 作者认为早发1型糖尿病可能需要加强心血管保护。
适用人群与场景
- 瑞典国家糖尿病登记库中1998年1月1日至2012年12月31日期间至少一次登记的1型糖尿病患者,按发病年龄分为0-10、11-15、16-20、21-25、26-30岁五组。
- 对照组为来自一般人群的匹配对照。
研究设计与关键结果
- 全国登记队列研究,纳入27 195例1型糖尿病患者和135 178例匹配对照,中位随访10年。
- 随访期间959例1型糖尿病患者和1501例对照死亡。
- 0-10岁发病组:全因死亡HR 4.11(95%CI 3.24-5.22),心血管死亡HR 7.38(3.65-14.94),非心血管死亡HR 3.96(3.06-5.11),心血管病HR 11.44(7.95-16.44),冠心病HR 30.50(19.98-46.57),急性心梗HR 30.95(17.59-54.45),卒中HR 6.45(4.04-10.31),心衰HR 12.90(7.39-22.51),房颤HR 1.17(0.62-2.20)。
- 26-30岁发病组:全因死亡HR 2.83(95%CI 2.38-3.37),心血管死亡HR 3.64(2.34-5.66),非心血管死亡HR 2.78(2.29-3.38),心血管病HR 3.85(3.05-4.87),冠心病HR 6.08(4.71-7.84),急性心梗HR 5.77(4.08-8.16),卒中HR 3.22(2.35-4.42),心衰HR 5.07(3.55-7.22),房颤HR 1.18(0.79-1.77)。
- 超额风险随发病年龄增大而降低,不同发病年龄组间差异可达5倍。
- 全因死亡率最高为1.9/10万人年(95%CI 1.71-2.11),见于1型糖尿病患者。
- 10岁前发病者女性寿命损失17.7年(95%CI 14.5-20.4),男性14.2年(12.1-18.2)。
证据类型、等级与局限
- 证据类型:全国登记队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,早发1型糖尿病可能需要加强心血管保护。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: People with type 1 diabetes are at elevated risk of mortality and cardiovascular disease, yet current guidelines do not consider age of onset as an important risk stratifier. We aimed to examine how age at diagnosis of type 1 diabetes relates to excess mortality and cardiovascular risk.
METHODS: We did a nationwide, register-based cohort study of individuals with type 1 diabetes in the Swedish National Diabetes Register and matched controls from the general population. We included patients with at least one registration between Jan 1, 1998, and Dec 31, 2012. Using Cox regression, and with adjustment for diabetes duration, we estimated the excess risk of all-cause mortality, cardiovascular mortality, non-cardiovascular mortality, acute myocardial infarction, stroke, cardiovascular disease (a composite of acute myocardial infarction and stroke), coronary heart disease, heart failure, and atrial fibrillation. Individuals with type 1 diabetes were categorised into five groups, according to age at diagnosis: 0-10 years, 11-15 years, 16-20 years, 21-25 years, and 26-30 years.
FINDINGS: 27 195 individuals with type 1 diabetes and 135 178 matched controls were selected for this study. 959 individuals with type 1 diabetes and 1501 controls died during follow-up (median follow-up was 10 years). Patients who developed type 1 diabetes at 0-10 years of age had hazard ratios of 4·11 (95% CI 3·24-5·22) for all-cause mortality, 7·38 (3·65-14·94) for cardiovascular mortality, 3·96 (3·06-5·11) for non-cardiovascular mortality, 11·44 (7·95-16·44) for cardiovascular disease, 30·50 (19·98-46·57) for coronary heart disease, 30·95 (17·59-54·45) for acute myocardial infarction, 6·45 (4·04-10·31) for stroke, 12·90 (7·39-22·51) for heart failure, and 1·17 (0·62-2·20) for atrial fibrillation. Corresponding hazard ratios for individuals who developed type 1 diabetes aged 26-30 years were 2·83 (95% CI 2·38-3·37) for all-cause mortality, 3·64 (2·34-5·66) for cardiovascular mortality, 2·78 (2·29-3·38) for non-cardiovascular mortality, 3·85 (3·05-4·87) for cardiovascular disease, 6·08 (4·71-7·84) for coronary heart disease, 5·77 (4·08-8·16) for acute myocardial infarction, 3·22 (2·35-4·42) for stroke, 5·07 (3·55-7·22) for heart failure, and 1·18 (0·79-1·77) for atrial fibrillation; hence the excess risk differed by up to five times across the diagnosis age groups. The highest overall incidence rate, noted for all-cause mortality, was 1·9 (95% CI 1·71-2·11) per 100 000 person-years for people with type 1 diabetes. Development of type 1 diabetes before 10 years of age resulted in a loss of 17·7 life-years (95% CI 14·5-20·4) for women and 14·2 life-years (12·1-18·2) for men.
INTERPRETATION: Age at onset of type 1 diabetes is an important determinant of survival, as well as all cardiovascular outcomes, with highest excess risk in women. Greater focus on cardioprotection might be warranted in people with early-onset type 1 diabetes.
FUNDING: Swedish Heart and Lung Foundation.
参考来源
- Rawshani A, Sattar N, Franzén S, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018. PMID: 30129464. doi:10.1016/S0140-6736(18)31506-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。